文献速递中枢神经肿瘤放疗

使用调强放疗(IMRT)或质子放疗的胶质母细胞瘤放疗—GRIPS试验(胶质母细胞瘤经IMRT或质子束放疗):一项多中心、前瞻性、开放标签、随机、双臂、III期研究的研究方案

Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy-GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study.
PubMed 文献 · Radiat Oncol · 2021-12-20

GRIPS试验为多中心、前瞻性、开放标签、随机、双臂、III期研究,比较调强光子放疗(标准组)与质子束放疗(试验组)治疗胶质母细胞瘤,计划入组326例,主要终点为治疗前4个月内CTC 2级及以上毒性累积发生率。

要点

  • GRIPS试验对比质子束放疗与调强光子放疗,计划入组326例胶质母细胞瘤患者。
  • 主要终点为治疗开始后前4个月内CTC 2级及以上毒性的累积发生率。
  • 放疗剂量为30×2 Gy(RBE)或33×1.8 Gy(RBE),低分割方案为15×2.67 Gy(RBE)。

核心结论

  • GRIPS研究旨在前瞻性评估质子束放疗的理论物理优势能否转化为治疗期间及治疗后最初几个月内毒性的临床降低。

研究设计与样本

  • 多中心、前瞻性、开放标签、随机、双臂、III期研究,比较调强光子放疗(标准组)与质子束放疗(试验组)。
  • 按「分割方案」(常规分割/低分割)、「室管膜下区受累」(是/否)和同步化疗(是/否)分层,计划入组326例患者。

主要发现

  • 一项初始回顾性配对分析显示,质子束放疗的理论物理优势在临床上也与治疗期间及治疗后最初几个月内毒性减少相关。

关键数值与推荐

  • 放疗剂量为30×2 Gy(RBE)或33×1.8 Gy(RBE),低分割方案为15×2.67 Gy(RBE)。
  • 主要终点为治疗开始后前4个月内CTC 2级及以上毒性的累积发生率。
  • 次要终点包括总生存期、无进展生存期、生活质量和神经认知。
  • 额外化疗(同步或辅助)或肿瘤电场治疗的剂量和频率按研究外的治疗标准执行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation therapy is an integral part of the multimodal primary therapy of glioblastomas. As the overall prognosis in this tumor entity remains unfavorable, current research is focused on additional drug therapies, which are often accompanied by increases in toxicity. By using proton beams instead of photon beams, it is possible to protect large parts of the brain which are not affected by the tumor more effectively. An initial retrospective matched-pair analysis showed that this theoretical physical benefit is also clinically associated with a reduction in toxicity during therapy and in the first few months thereafter. METHODS/DESIGN: The GRIPS trial is a multicenter, prospective, open-label, randomized, two-arm, phase III study using either intensity modulated photon radiation techniques (standard arm) or proton beam radiotherapy (experimental arm). Additionally, patients are stratified according to "fractionation scheme" (normofractionated/hypofractionated), "subventricular zone involvement" (yes/no) and concurrent chemotherapy (yes/no) and the planned case number is 326 patients. Radiation therapy is performed with a dose of 30 × 2 Gy(RBE) or 33 × 1.8 Gy(RBE), or for patients treated according to the hypofractionation protocol with 15 × 2.67 Gy(RBE). A possible administration of additional chemotherapy (concurrent or adjuvant) or tumor treating fields is applied in dosage and frequency according to the therapy standard outside of this study. The primary endpoint is the cumulative rate of toxicity CTC grade 2 and higher in the first 4 months. Secondary endpoints include overall survival, progression-free survival, quality of life, and neurocognition. DISCUSSION: Aim of the GRIPS study is to prospectively assess whether the theoretical physical advantage of proton beam radiotherapy will translate into a clinical reduction of toxicity during and in the first months after therapy. Trial registration ClinicalTrials (NCT): NCT04752280.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. König L, Jäkel C, von Knebel Doeberitz N, et al. Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy-GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study. Radiat Oncol. 2021. PMID: 34930368. doi:10.1186/s13014-021-01962-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。